Results 191 to 200 of about 32,756 (253)

Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan‐O‐AP and LixiLan‐L‐CN

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the impact of iGlarLixi on the depth of glycaemic control, glycaemic variability (GV) and postprandial glucose (PPG) control versus insulin glargine 100 U/mL (iGlar) or lixisenatide (Lixi) in Asian Pacific individuals with type 2 diabetes (T2D).
Jiaying Ni, Jingyi Lu, Fei Gao, Min Li, Minlu Zhang, Qin Du, Lei Kang, Danfeng Peng, Jian Zhou   +8 more
wiley   +1 more source

Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Cardiovasc Ther
Zawadzki M, Karczewska-Kupczewska M.
europepmc   +1 more source

Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the real‐world effectiveness, safety and patient‐reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2DM) receiving routine outpatient care in a cost‐constrained setting. Methods This 30‐week, prospective, multicentre, non‐interventional study enrolled adults with T2DM initiating ...
Arshad Hussain, Muhammad Umar Wahab, Saleem Qureshi, Umar Yousaf Raja, Atif Munir, Shahnawaz Gardezi, Musarrat Iqbal, Bilal Afzal, Muhammad Daoud Butt, Siew Chin Ong   +9 more
wiley   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control. [PDF]

Pharmaceuticals (Basel)
Xanthopoulou M, Evangelidis P, Poulis D, Gavriilaki E, Kotsiou N, Antza C, Kotsis V, Doxani C, Mprotsis T, Zintzaras E, Anyfanti P.   +10 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, EarlyView.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Rev Cardiovasc Med
West L, Patolia H, Chapman B, Laffin L, Vest AR, Sauer AJ, Martyn T.   +6 more
europepmc   +1 more source

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Bilal AR, Ibrahim M, Arfin SMW, Bilal AR, Balach R, Qureshi S, Gaba H, Collins P, Ahmed R, Waqas SA.   +9 more
europepmc   +1 more source